Helperby Therapeutics announces study results active against the WHO Critical Priority Carbapenem resistant bacterial pathogens

 

Helperby Therapeutics announces study results demonstrating promise of its unique combination antibiotic therapy - active against the WHO Critical Priority Carbapenem resistant bacterial pathogens 

 The combination of azidothymidine (AZT) and low-dose colistin shows synergistic antibiotic activity against carbapenem and colistin-resistant Enterobacteriaceae (CRE) infections. 

 

Click here to read the full paper

---